Clinical Trial Update: ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma [Phase 3]

View source ↗

Summary

Clinical trial update for ASKB589 in combination with CAPOX and a PD-1 inhibitor for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• ASKB589
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• PD-1 inhibitor (unspecified)

Snippet

Sponsor: AskGene Pharma, Inc. | Conditions: Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING